← Leaderboards
Paul J Fadel
Ut Southwestern Medical Center
$5,937,069
Attributed
$5,937,069
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $832.4K · FY2007–23$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,937,069 · 6
By mechanism
R01$3,710,396 · 2
P01$1,718,694 · 2
R21$407,388 · 1
F32$100,591 · 1
Top collaborators
No co-investigators on record.
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Qi Fu$9,501,546
- Benjamin D Levine$13,458,852
- Michael Douglas Nelson$6,932,903
- Edward Livingston$1,498,560
- Peter Noel Van Buren$842,590
Others in their field
Top investigators on “Cardiovascular System”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Judith S Hochman · New York University School Of Medicine$110,228,771
Research focus
Cardiovascular SystemMuscleRandomizedBlood FlowBlood VesselsNerveBlood PressureMediatingResponsePeripheralImpairmentRestCardiacExerciseAutomobile DrivingElderlyHemodynamicsPressureReportingDoppler UltrasoundEstrogensPlacebosPostmenopauseBaroreflex
Grant awards (20)
Targeting skeletal muscle to improve exercise capacity in heart failure with preserved ejection fraction.$343,330
P01 · FY2023 · HL · contact PI
Targeting skeletal muscle to improve exercise capacity in heart failure with preserved ejection fraction.$339,478
P01 · FY2022 · HL · contact PI
Targeting skeletal muscle to improve exercise capacity in heart failure with preserved ejection fraction.$303,214
P01 · FY2021 · HL · contact PI
Targeting skeletal muscle to improve exercise capacity in heart failure with preserved ejection fraction.$336,905
P01 · FY2020 · HL · contact PI
Targeting Sympathetic Overactivity in CKD patients: Mechanisms & Novel Therapies$436,639
R01 · FY2019 · HL · contact PI
Autonomic Circulatory Control in Patients with HFpEF$395,767
P01 · FY2019 · HL · contact PI
Targeting Sympathetic Overactivity in CKD patients: Mechanisms & Novel Therapies$432,755
R01 · FY2018 · HL · contact PI
Targeting Sympathetic Overactivity in CKD patients: Mechanisms & Novel Therapies$421,318
R01 · FY2017 · HL · contact PI
Targeting Sympathetic Overactivity in CKD patients: Mechanisms & Novel Therapies$410,204
R01 · FY2016 · HL · contact PI
Aging, Sex, and Neural Cardiovascular Control During Dynamic Exercise$370,013
R01 · FY2012 · HL · contact PI
Aging, Sex, and Neural Cardiovascular Control During Dynamic Exercise$373,750
R01 · FY2011 · HL · contact PI
Aging, Sex, and Neural Cardiovascular Control During Dynamic Exercise$373,750
R01 · FY2010 · HL · contact PI
Aging, Sex, and Neural Cardiovascular Control During Dynamic Exercise$373,750
R01 · FY2009 · HL · contact PI
Aging, Sex, and Neural Cardiovascular Control During Dynamic Exercise$163,277
R01 · FY2009 · HL · contact PI
Aging, Sex, and Neural Cardiovascular Control During Dynamic Exercise$354,940
R01 · FY2008 · HL · contact PI
Sympathetic overactivity & hypertension in ERSD: A role for ADMA$183,138
R21 · FY2008 · DK · contact PI
Sympathetic overactivity & hypertension in ERSD: A role for ADMA$224,250
R21 · FY2007 · DK · contact PI
Estrogen and Sympathetically Mediated Vasoconstriction$15,851
F32 · FY2004 · HL
Estrogen and Sympathetically Mediated Vasoconstriction$46,420
F32 · FY2003 · HL
Estrogen and Sympathetically Mediated Vasoconstriction$38,320
F32 · FY2002 · HL